The document summarizes information about Arab Company For Pharmaceutical Industries, including its vision, mission, location, product portfolio, licenses, factory layout, water treatment process, and composition of various hemodialysis solutions. The company is committed to providing high quality medical products and services from its location in Banyswaif, Egypt. It produces a range of hemodialysis solutions and aims to create a future worth living for people through reliable performance and sustainable practices.

1. Arab Company For
Pharmaceutical Industries

2. Our Vision
“Creating a future worth living for people across the globe everyday”
The highest quality standards are our benchmark, this is our
commitment to our patients, our partners in the healthcare system
who trust us in the reliable performance, and the future of Arab
medical industries.

3. Our Mission
The unique location of Arab medical industries in the city of
‘Banyswaif’ Egypt (links between the north and south of Egypt). Our
company is committed to provide high quality products, services
and bringing the optimal sustainable medical and professional
practices to patient care, we are committed to honesty, integrity,
respect and dignity in our work and business relations with our
employees and partners.

4. Location :
• Byad el Arab -Banysweif conjunction
point between north and south of Egypt ---
130km far from Cairo
• Area:
25000m2

5. Product portfolio (existing)
• Hemodialysis:
• Acetate; 5, 10, 20L
• Acid concentrate with acetic acid: 5, 10, 20L
• Acid concentrate with citric acid: 5, 10, 20L
• Sodium Bicarbonate: bags; 500, 650, 840gm

6. Product portfolio

7. • Hemodialysis: Sodium Bicarbonate cartridge
• Disinfectant: citric acid cartridge 32gm
• Peritoneal dialysis (PD):
– CAPD
– Night PD
• Hemofiltration
• Hemodiafiltration
Product portfolio (future)

8. licenses
• in addition to the official licenses
( Industrial, MOH) we have ISO 13485 and CE
Mark from International Bodies (QS- SGS)

9. ISO 13485

10. CE Certificate

11. Factory Layout

12. Water Treatment

13. Water Treatment

14. Water Treatment

15. Water Treatment

16. Gowning Area

17. Gowning Area

18. Gowning Area

19. Sampling Laminar Flow

20. Weighing Laminar Flow

21. Preparation Area

23. Preparation Area

24. Filling room

25. Filling room

26. Filling room

27. Receiving Area

28. Finished Product store

29. Chemistry Lab

30. Chemistry Lab

31. Micro Lab

32. Micro Lab- L.F

33. Composition of hemodialysis Acid
concentrated solutions after dilution
ref Code Na⁺ K⁺ Ca⁺⁺ Mg⁺⁺ Cl¯ Acetic
acid
citrate glucose
1 AC001 105 2 1.5 0.5 111 2 - -
2 AC002 105 2 1.5 0.5 111 3 - -
3 AC003 105 2 1.75 0.5 111.5 3 - -
4 AC004 105 2 1.5 0.5 111 2 - -
5 AC005 103 2 1.75 0.5 109.5 3 - -
6 AC006 103 2 1.75 0.5 109.5 3 - 1gm/l
7 AC007 103 2 1.25 0.5 108.5 3.5 - -

34. Composition of hemodialysis Acid
concentrated solutions after dilution
ref Code Na⁺ K⁺ Ca⁺⁺ Mg⁺⁺ Cl¯ Acetic
acid
citrate glucose
8 AC008 103 2 1.5 0.5 109 3.5 - -
9 AC009 103 2 1.0 0.5 108 3.5 - -
10 AC010 103 1 1.75 0.5 108.5 3 - -
11 AC011 102 4 1.75 0.5 110.5 2 - -
12 AC012 102 - 1.75 0.5 106.5 2 - 2gm/l

35. Composition of hemodialysis Acid
concentrated solutions after dilution
ref Code Na⁺ K⁺ Ca⁺⁺ Mg⁺⁺ Cl¯ Acetic
acid
citrate glucose
13 CTR001 100.3 1.0 1.25 0.5 104.5 0.3 0.8
14 CTR002 100.3 1.0 1.25 0.5 104.5 0.3 0.8 1gm/l
15 CTR003 100.3 2.0 1.25 0.5 105.5 0.3 0.8 -
16 CTR004 100.3 2.0 1.25 0.5 105.5 0.3 0.8 1gm/l

36. Composition of hemodialysis Acetate
concentrated solutions after dilution
ref Code Na⁺ K⁺ Ca⁺⁺ Mg⁺⁺ Cl¯ Acetic
acid
citrate glucose
17 ATC001 138 1.5 1.25 0.75 107 36.5 - -
18 ATC002 134 2 2 0.75 105 36.5 - -
19 ATC003 134 2 2 0.75 105 36.5 - 1gm/l
20 ATC004 134 1.5 1.25 0.75 103 36.5 - -
21 ATC005 135 1.5 1.5 0.75 106 35 - -

37. Citrate dialysate(CD)
• physiological and biocompatible
• contains 0.8mmol/l of citrate. The anticoagulation effect is
confined to the dialyzer and the venous side of the dialysis set
up
• Low risk of significant hypocalcaemia or hypomagnesemia
• No change in treatment routine or equipment required to
use.
• a safe effective way to provide better dialysis therapy.
• In the EU and the US citrate dialysate is approved for clinical
use.

38. • Citrate dialysis has been shown to provide improved treatment for patients on routine long-
term hemodialysis when compared to currently used dialysate formulations. In addition citric
dialysate has the following advantages:
• Improves dialysis in patients who are "dialyzer clotters"
• Enables heparin-free dialysis of patients with antibodies to heparin (HIT) or those who are
allergic to heparin
• Enables heparin-free dialysis of patients with acute renal failure who are at risk of bleeding
• Reduces post-dialysis bleeding, if heparin is reduced
• Eliminates or reduces Heparin need in CRF patients
• Increases dialysis dose Kt/V
• Corrects acidosis
Indications/Product benefits

39. Product information
• The liquid acid concentrate part A is
available in 5, 10, 20L jerry cans.

40. Ultra-pure dialysate
• The presence of high levels of bacteria and endotoxins in the
dialysate can lead to a substantial degree of inflammation.
The recent studies have shown that in many dialysates there
are proinflammatory bacterial fragments which can pass
through the dialysis membrane (1.25 daltons).

41. Ultra-pure dialysate requirements:
• Maximal endotoxin level 0.03 EU/ml
Pharmacopeal limit 0.5 EU/ml
• Maximal bacterial level 0.1 CFU/ml

42. Other advantages of ultra-pure
dialysate:
• Lower plasma level of C-reactive protein and
interleukin-6.
• Increase the plasma albumin value
• Reduce the dose of erythropoietin

43. Cedro CLM
For decalcification and disinfection of
haemodialysis machines
• Disinfection and decalcification in one process
• excellent removal of CaCO3
• Dissolution of blood residues
• active ingredients composed of natural materials
• biodegradable
• non-toxic (LD50> 2000 mg/kg)

44. Cedro CLM
CedroCLM at 84oc has a broad spectrum of
microbiological activity:
• bactericidal
• fungicidal
• virus inactivating (HBV,HCV,HIV)

45. Cedro CLM